Cargando…

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan

The objective of this study was to evaluate the efficacy, pharmacokinetics, and safety of adalimumab in patients with polyarticular juvenile idiopathic arthritis (JIA) in Japan. Patients aged 4 to 17 years were enrolled in a single-arm, open-label, multicentre study of adalimumab. Patients weighing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imagawa, Tomoyuki, Takei, Syuji, Umebayashi, Hiroaki, Yamaguchi, Kenichi, Itoh, Yasuhiko, Kawai, Toshinao, Iwata, Naomi, Murata, Takuji, Okafuji, Ikuo, Miyoshi, Mari, Onoe, Yasuhiro, Kawano, Yoshifumi, Kinjo, Noriko, Mori, Masaaki, Mozaffarian, Neelufar, Kupper, Hartmut, Santra, Sourav, Patel, Gina, Kawai, Shinichi, Yokota, Shumpei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505492/ https://www.ncbi.nlm.nih.gov/pubmed/23053683 http://dx.doi.org/10.1007/s10067-012-2082-5

Ejemplares similares

Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
por: Mori, Masaaki, et al.
Publicado: (2008)

Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
por: Hara, Ryoki, et al.
Publicado: (2019)

Correlation between clinical indices and findings of joint ultrasonography in juvenile idiopathic arthritis with adalimumab therapy
por: Hara, Ryoki, et al.
Publicado: (2011)

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
por: Kobayashi, Shigeto, et al.
Publicado: (2011)

PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
por: Kingsbury, D, et al.
Publicado: (2013)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
por: Nakaoka, Yoshikazu, et al.
Publicado: (2018)

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

Chronic granulomatous disease with pulmonary mass-like opacities secondary to hypersensitivity pneumonitis: a case report
por: Katsuya, Yuki, et al.
Publicado: (2014)

Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
por: Mozaffarian, Neelufar, et al.
Publicado: (2016)

Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction
por: Okuyama, Mai, et al.
Publicado: (2019)

A promoter haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population
por: Sugiura, Tomoko, et al.
Publicado: (2006)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Childhood Arthritis and Rheumatology Research for Dreams Come True Remission
por: Takei, Syuji
Publicado: (2022)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Gene-Activated Matrix Comprised of Atelocollagen and Plasmid DNA Encoding BMP4 or Runx2 Promotes Rat Cranial Bone Augmentation
por: Umebayashi, Mayumi, et al.
Publicado: (2015)

Ultrasonographic assessment reveals detailed distribution of synovial inflammation in Blau syndrome
por: Ikeda, Kei, et al.
Publicado: (2014)

Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
por: Minden, Kirsten, et al.
Publicado: (2014)

Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis
por: Miyamae, Takako, et al.
Publicado: (2010)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan
por: Yokota, Shumpei, et al.
Publicado: (2016)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Supramolecular Copolymerization of Bichromophoric Chiral and Achiral Perylenediimide Dyes
por: Yonezawa, Shumpei, et al.
Publicado: (2021)

Algebraic analysis of singular perturbation theory
por: Kawai, Takahiro, et al.
Publicado: (2005)

A low-birth-weight risk assessment scale: development and validation through a questionnaire-based survey
por: Sonoda, Kazuko, et al.
Publicado: (2019)

Patient-reported outcomes in patients with primary immunodeficiency diseases in Japan: baseline results from a prospective observational study
por: Kanegane, Hirokazu, et al.
Publicado: (2023)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
por: Burmester, Gerd-Rűdiger, et al.
Publicado: (2015)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study
por: Price, Elizabeth, et al.
Publicado: (2022)

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis
por: Sakurai, Toshiharu, et al.
Publicado: (2020)

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
por: Kingsbury, Daniel J., et al.
Publicado: (2014)

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Virtual turning points
por: Honda, Naofumi, et al.
Publicado: (2015)

Tricho-hepato-enteric syndrome with novel SKIV2L gene mutations: A case report
por: Hiejima, Eitaro, et al.
Publicado: (2017)

Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function
por: Jain, Sunil M., et al.
Publicado: (2022)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

A pregnant woman with thymoma-associated pure red cell aplasia
por: Shibata, Megumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pk3nk5pt5e91ok6bsndvbu58ed